PriceTargets.com logo

Summit Therapeutics - SMMT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 128.57%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.50 As of 04/19/2024 01:00 AM ET
▼ -0.01 (-0.28%)

This chart shows the closing price for SMMT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Summit Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SMMT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SMMT

Analyst Price Target is $8.00
▲ +128.57% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Summit Therapeutics in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 128.57% upside from the last price of $3.50.

This chart shows the closing price for SMMT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Summit Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/26/2024Stifel NicolausInitiated CoverageBuy$8.00Low
12/6/2021HC WainwrightReiterated RatingHoldLow
11/18/2020HC WainwrightDowngradeBuy ➝ NeutralLow
5/1/2020HC WainwrightReiterated RatingBuy$4.00High
3/19/2020HC WainwrightInitiated CoverageBuy$4.00Medium
10/15/2019HC WainwrightSet TargetBuy$2.00Low
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 7 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 7 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 7 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Summit Therapeutics logo
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $3.50
Low: $3.34
High: $3.55

50 Day Range

MA: $4.16
Low: $3.28
High: $5.07

52 Week Range

Now: $3.50
Low: $1.30
High: $5.22

Volume

1,727,400 shs

Average Volume

2,225,034 shs

Market Capitalization

$2.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Summit Therapeutics?

The following Wall Street analysts have issued reports on Summit Therapeutics in the last year: Stifel Nicolaus, and StockNews.com.
View the latest analyst ratings for SMMT.

What is the current price target for Summit Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Summit Therapeutics in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 128.6%. Stifel Nicolaus has the highest price target set, predicting SMMT will reach $8.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $8.00 for Summit Therapeutics in the next year.
View the latest price targets for SMMT.

What is the current consensus analyst rating for Summit Therapeutics?

Summit Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SMMT will outperform the market and that investors should add to their positions of Summit Therapeutics.
View the latest ratings for SMMT.

What other companies compete with Summit Therapeutics?

Other companies that are similar to Summit Therapeutics include Evotec, Corcept Therapeutics, Merus, Janux Therapeutics and Vera Therapeutics. Learn More about companies similar to Summit Therapeutics.

How do I contact Summit Therapeutics' investor relations team?

Summit Therapeutics' physical mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company's listed phone number is 650-460-8308 and its investor relations email address is [email protected]. The official website for Summit Therapeutics is www.summitplc.com. Learn More about contacing Summit Therapeutics investor relations.